通讯作者: 陈丰穗, n19kchy@163.com

DOI：10.12201/bmr.202604.00069

Study on the efficacy of lenvatinib combined with Huachansu in the treatment of advanced hepatocellular carcinoma

• 摘要：目的：研究仑伐替尼与华蟾素联合治疗中晚期肝细胞癌的具体效果。方法：对中国人民解放军联勤保障部队第九〇〇医院（以下简称第九〇〇医院）2023年1月~2025年8月期间收治的62例中晚期肝细胞癌患者的临床资料展开回顾性分析，按照治疗方法的不同将其分为对照组（采用仑伐替尼单药治疗）和研究组（采用仑伐替尼与华蟾素联合治疗）各31例，对比两组患者的近期疗效、不良反应发生率及治疗前后肿瘤标志物、血液学指标、肝功能指标的变化情况。结果：两组疾病控制率对比研究组更高（P＜0.05）；两组不良反应总发生率对比差异无统计学意义（P＞0.05）；治疗后两组甲胎蛋白（alpha-fetoprotein，AFP）、维生素k缺乏或拮抗剂Ⅱ型诱导蛋白（protein induced by vitamin k absence or antagonist-Ⅱ，PIVKA-Ⅱ）水平、血小板与淋巴细胞比值（platelet-to-lymphocyte ratio，PLR）、中性粒细胞与淋巴细胞比值（neutrophil-to-lymphocyte ratio，NLR）、谷丙转氨酶(alanine aminotransferase，ALT)、谷草转氨酶(aspartate aminotransferase，AST)水平均较治疗前有所降低且研究组较对照组低（P＜0.05）。结论：仑伐替尼与华蟾素联合治疗可更有效得提高中晚期肝细胞癌患者的疾病控制率，降低其肿瘤标志物水平，改善其预后及肝功能，同时两者联用不会增加不良反应。

  关键词： 仑伐替尼; 华蟾素; 中晚期肝细胞癌; 耐药性; 肝功能

   

  Abstract: Objective:To study the specific effect of the combination therapy of lenvatinib and Huachansu in the treatment of advanced hepatocellular carcinoma.Methods:A retrospective analysis of clinical data from 62 patients with mid-to-late stage hepatocellular carcinoma admitted to The 900th Hospital of the PLA Joint Logistic Support Force (hereinafter referred to as The 900th Hospital) between January 2023 and August 2025. Based on different treatment regimens, the patients were divided into a control group (treated with lenvatinib monotherapy) and a study group (treated with lenvatinib combined with huachansu), each comprising 31 cases. Compare the short-term efficacy, incidence of adverse reactions, and changes in tumor markers, hematological parameters, and liver function indicators before and after treatment between the two patient groups.Results:Disease control rates were significantly higher in the study group compared to the control group (P<0.05); The overall incidence of adverse reactions showed no statistically significant difference between the two groups (P>0.05); After treatment, levels of alpha-fetoprotein (AFP), protein induced by vitamin k absence or antagonist-Ⅱ (PIVKA-II), platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocyte ratio (NLR), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) levels decreased compared to pre-treatment levels in both groups, with the study group showing lower levels than the control group (P<0.05).Conclusion:The combination therapy of lenvatinib and huachansu more effectively improves disease control rates in patients with advanced hepatocellular carcinoma, reduces tumor marker levels, enhances prognosis and liver function, while not increasing adverse reactions.

  Key words: Lenvatinib; Huachansu; Advanced hepatocellular carcinoma; Drug resistance; Liver function

  提交时间：2026-04-09

  版权声明：作者本人独立拥有该论文的版权，预印本系统仅拥有论文的永久保存权利。任何人未经允许不得重复使用。
• html

• 图表

• 李雯馨, 徐琛. ACR CEUS LI-RADS在有无高危风险人群中对肝细胞癌的诊断价值. 2026. doi: 10.12201/bmr.202601.00041

  陈惠怡, 路明, 钟培松, 任洪磊, 殷方兰▲. 肝癌早期筛查的精准化研究进展. 2025. doi: 10.12201/bmr.202512.00013

  肖亚轩, 王雅静, 彭佩, 张雪. 基于“肠道菌群-胆汁酸”轴探讨肝癌肝郁脾虚的病机实质. 2025. doi: 10.12201/bmr.202506.00030

  方晢伊, 祝雯珺, 黄葭燕. 全球抗生素耐药性研究进展的文献计量分析. 2022. doi: 10.12201/bmr.202207.00021

  乔明旭, 胡伟. 派安普利联合化疗治疗晚期非鳞非小细胞肺癌的疗效分析. 2025. doi: 10.12201/bmr.202508.00045

  陈煜, 李博文, 杨谨华, 刘洋, 魏云巍. 肝癌瘤内菌群的研究进展及未来靶向治疗前景. 2024. doi: 10.12201/bmr.202412.00033

  王国超, 金敏, 通信作者:金敏. 逆转细菌耐药性中药及其作用机制研究进展. 2025. doi: 10.12201/bmr.202503.00056

  赵浩森, 曲颜丽. 真实世界中局部晚期胃/胃食管结合部腺癌患者术前化疗的疗效及安全性. 2024. doi: 10.12201/bmr.202409.00052

  胡芷晴, 潘珊, 朱巍立. 铁死亡在逆转卵巢癌铂耐药中的研究进展. 2025. doi: 10.12201/bmr.202512.00070

  邓锐. 肝细胞癌非手术治疗的现况研究与展望. 2025. doi: 10.12201/bmr.202510.00062

• 序号	提交日期	编号	操作
  1	2026-03-23	10.12201/bmr.202604.00069V1	下载

• 公开评论  匿名评论  仅发给作者 提交评论